Medical Cannabis Import Rules: UK Border Force Updated Guidelines

UK Border Force has published revised operational guidance covering the importation of cannabis-based medicinal products (CBMPs). The updated guidelines apply to both commercial pharmaceutical importers and individual patients travelling to the UK with personally prescribed cannabis medicines.

For Commercial Importers

Companies importing licensed CBMPs into the UK must ensure all shipments are accompanied by the correct Schedule 2 import licence, issued by the Home Office Drugs Licensing and Compliance Unit. The revised guidance clarifies that Import Licences are product-specific and batch-specific — a single licence cannot cover multiple formulations or multiple shipments within a single authorisation.

For Patients Travelling with Prescribed Medicine

• Patients must carry the original prescription or a patient identification certificate issued by the prescribing clinic
• The quantity carried must not exceed 30 days supply
• Products must be in original manufacturer packaging with patient name clearly labelled
• A letter from the prescribing doctor confirming diagnosis and treatment rationale is strongly recommended

International Travel Caution

Border Force guidance explicitly states that UK patients carrying prescribed cannabis medicine abroad should check the legal status of CBMPs in their destination country before travel. The guidance notes that possession of cannabis-based medicines is illegal in numerous jurisdictions regardless of the prescribing country's regulations.

"Patients travelling internationally with prescribed cannabis medicine must understand that UK law does not confer any right to carry such medicines across foreign borders."

The updated guidance has been welcomed by patient advocacy organisations, who note that the previous framework contained ambiguities that caused unnecessary difficulties for patients at UK ports of entry.